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ABSTRACT
Gastric cancer is a disease that develops from the lining of the stomach, whereas Parkinson’s disease is a longterm degenerative disorder of the central nervous system that mainly affects the motor system. Although these
two diseases seem to be distinct from each other, increasing evidence suggests that they might be linked. To
explore the linkage between these two diseases, differentially expressed genes between the diseased people
and their normal controls were identified using the barcode algorithm. This algorithm transforms actual gene
expression values into barcode values comprised of 1’s (expressed genes) and 0’s (silenced genes). Once the
overlapped differentially expressed genes were identified, their biological relevance was investigated. Thus,
using the gene expression profiles and bioinformatics methods, we demonstrate that Parkinson’s disease and
gastric cancer are indeed linked. This research may serve as a pilot study, and it will stimulate more research to
investigate the relationship between gastric cancer and Parkinson’s disease from the perspective of gene
profiles and their functions.
movements [2]. The causes of Parkinson’s disease and
gastric cancer are very complicated, and increasing
evidence supports the involvement of both genetic and
environmental factors.

INTRODUCTION
Gastric cancer (GC), also known as stomach cancer,
develops from the cells lining of the stomach. In 2018,
more than one million new cases of gastric cancer were
diagnosed, and an estimated 783,000 associated deaths
occurred. One out of 12 cancer deaths worldwide
resulted from GC, making it the fifth most common
cancer and the third leading cause of death due to
cancer [1]. Gastric cancer poses a particularly serious
health problem in Eastern Asia. Parkinson’s disease is a
long-term degenerative disorder of the central nervous
system that mainly affects the motor system. It is
currently listed as the second most prevalent
neurodegenerative disorder after Alzheimer’s disease
and the most common disorder affecting body
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It is believed that the gastrointestinal tract comprises an
intrinsic nervous system — the enteric nervous system
(ENS). Referred to as “the second brain” [3], the ENS
regulates the gastrointestinal tract’s motility and owns
neuroendocrine functions. The ENS interacts bidirectionally with the Central Nervous Systems (CNS),
in a connection referred to as the “brain-gut axis” [4],
which is composed of neural pathways in the CNS,
autonomic nervous system, and the hypothalamicpituitary-adrenal axis. A large number of patients with
Parkinson’s disease experience constipation, abdominal
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distension, and other gastrointestinal symptoms before
they experience motor symptoms [5]. More importantly,
dysbiosis of gut microbiota plays a critical role in the
pathogenesis of Parkinson’s disease, such as [6]. On the
other hand, gastrointestinal symptoms and microbiome
dysbiosis frequently occur in patients with gastric
cancer [7]. Especially, increased gut permeability
promotes the leakage of bacteria and their products into
the blood, leading to the maturation of antigenpresenting cells and thus the stimulation of
inflammatory pathways that are of crucial importance in
these two diseases.

Microarray and RNA-sequence techniques enable
monitoring expression changes of thousands of genes
simultaneously. For both gastric cancer and Parkinson’s
disease, numerous microarray and RNA-Sequence
experiments such as [22–32] have been conducted to
distinguish between the diseased patients and normal
controls, or predict the progression of the two diseases,
with the aid of a variety of bioinformatics tools and
statistical methods. To the best of our knowledge, no
investigation has been carried out to explore the link
between gastric cancer and Parkinson’s disease, using
the gene expression profiles generated through either
microarray or RNA-Sequencing. The objective of this
study is to bridge this gap by using gene expression
profiles and the barcode algorithm [33] to investigate
the potential association between the two diseases.

Epidemiological studies [8–12] have suggested that
patients with Parkinson’s disease have a reduced risk of
developing cancers, including gastric cancer, compared
to people who do not have Parkinson’s disease.
Nevertheless, other studies have showed a positive
association between Parkinson’s disease and cancers,
that is, an increased risk of cancers in patient with
Parkinson’s disease [13, 14]. For instance, for gastric
cancer, the hazard ratio was 1.59 (95% CIs: 1.30-1.94)
by Lin et al. [14], who attributed the inconsistency to
the fact that most of those epidemiological studies were
carried out upon the Western population, while their
study was performed in Taiwan. Therefore, Lin et al.
[14] concluded that the race or/and environmental
exposures have an interactive effect on the association
between cancers and Parkinson’s disease. Also, the
Columbia Open Health Data (COHD) [15], which is
based on electronic health records (EHR), indicated that
the concurrence of Parkinson’s disease and gastric
cancer is significantly higher than what expected by
chance (odds ratio=2.02, p=2.23×10-6). This implies
that both diseases are positively related. It is worth
noting that patients in the electronic health records may
not represent the general population; thus, the
association between the two diseases may be biased.
Therefore, it is natural to speculate that Parkinson’s
disease and gastric cancer may be linked.

RESULTS
Differentially expressed genes
For gastric cancer, 2,114 differentially expressed genes
(DEGs) between the patients and the normal controls
were identified. Among them, 1,296 exhibited a higher
expressed proportion, and 818 had a higher silenced
proportion higher in the gastric cancer patients
compared to the normal controls. For Parkinson’s
disease, 36 DEGs were identified. Of them, 33 genes
had the propensity of being expressed higher in the
disease group than that in the control group. Between
the two sets of DEGs, 15 genes overlapped on each
other (Fisher’s exact test: p=0.033). The gene symbols
for the 15 overlapping genes are presented in Figure 1A,
and the odds ratios (ORs) and false discovery rates
(FDR) stratified by the gastric cancer cohort and the
Parkinson’s disease cohort are listed in Table 1. Of
note, in gastric cancer, several overlapped genes had
extreme ORs (either 0 or infinite), while in Parkinson’s
disease the ORs were basically moderate.
All genes except GPX3, ZBTB16, and KCNQ1 have OR
of >1 for gastric cancer, whereas all genes have OR of
>1 for Parkinson’s disease, suggesting that for a patient
who has either Parkinson’s disease or gastric cancer,
the status of 12 genes is highly likely to be un-silenced.
This might imply that when a person suffers from one
disease, the likelihood of having the other disease tends
to increase, which is consistent with the results of a
previous epidemiology study conducted in Taiwan [14]
and the high concurrent rate between these two
diseases indicated by the COHD database [15].
Nevertheless, Lin’s study [14] indicated that race might
play an interactive role on the association between
Parkinson’s disease and cancers. Thus, for the Asians,
this association tends to positive, but for the
Caucasians, this association is more likely to be

At the molecular level, studies suggest that
neurodegenerative disorders (including Alzheimer’s
disease, Parkinson’s disease, and Huntington’s disease)
and cancers (including lung cancer, liver cancer, and breast
cancer) are linked to each other with respect to somatic
mutations, mRNAs or microRNAs, such as [16–19].
However, only a few of the studies focused on the specific
association between Parkinson’s disease and gastric cancer
from this perspective [20, 21]. For example, Hu and
colleagues [20] demonstrated that a specific miRNA, miR148a, is not only a potential tumor suppressor that inhibits
gastric cancer metastasis, but is also involved in
neurological development and functions. In particular, the
expression level of miR-148a is lower in patients with
Parkinson’s disease compared to that in normal controls.
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negative. Since no large Western gastric cancer cohort
or Asian Parkinson’s disease cohort on the same
microarray platform is available on the GEO database,
thus, whether the statement is true cannot be verified
using the proposed procedure in this study. Further
investigation is warranted. In contrast, the COHD
database is based on electronic health records, which
may introduce biases to the estimation of the
concurrent rate of the two diseases.

them, three enriched biological process terms were
commonly shared by the Parkinson’s disease DEGs and
the gastric cancer DEGs. Fifty-one GO chemical
component terms were indicated to be enriched by the
gastric cancer DEGs, none was enriched by the
Parkinson’s disease DEGs. In terms of GO molecular
function and KEGG pathway, the numbers are 7 and 17
for gastric cancer DEGs, 0 and 0 for Parkinson’s disease
DEGs, respectively. Therefore, no overlapped pathways
were found between gastric cancer and Parkinson’s
disease regarding the GO molecular function terms, the
GO chemical component terms, or KEGG pathways. In
Figure 1B, the overlapped GO biological process terms
along with their corresponding false discovery rates are
presented. Many review articles indicated that both cell
proliferation and differentiation as well as ubiquitinproteasome system play critical roles in the two diseases
[34–37].

Lastly, a respective logistic regression model with 15
overlapped genes as predictors was fit for either gastric
cancer or Parkinson’s disease microarray dataset. The
predictive capacity of resulting 15-gene signatures for
gastric cancer and Parkinson’s disease was validated on
external datasets. As shown by the ROC curves in
Figure 2, the list of 15-genes was validated to perform
fairly well; especially for gastric cancer, it achieved an
AUC statistic of 0.93.

The three overlapped GO biological process terms
deserve further investigation, which may facilitate
deciphering the association between Parkinson’s disease
and gastric cancer at the gene set level, where the
involved genes work in coordination to influence a
phenotype of interest.

Pathway enrichment analysis
In the GO biological process category, 313 terms were
enriched by the gastric cancer DEGs, and 10 terms were
enriched by the Parkinson’s disease DEGs. Among

Figure 1. Venn-diagrams for differentially expressed genes identified by gastric cancer cohort and Parkinson’s disease
cohort. (A) On the gene level. (B) On the level of enriched Gene Ontology annotation. PD, Parkinson’s disease; GC, gastric cancer; GO, gene
ontology; BP, biological process. The gene symbols indicated by the GeneCards database to directly associate with gastric cancer and
Parkinson’s disease are highlighted in green. Of note, on the gene level the overlapped rate of gastric cancer and Parkinson’s disease is
significant according to a Fisher’s exact test (p=0.033).
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Table 1. Overlapped differentially expressed genes by gastric cancer and
Parkinson’s disease cohorts.

CTSD
GPX3
SPINT1
LTBR
UBE2M
NUP98
CEBPA
KCNQ1
GMDS
ABHD2
ZBTB16
CSNK1D
RNF19B
SRA1
90-=

Gastric cancer
OR
FDR
13.073
4.43×10-23
0
1.70×10-26
4.134
3.27×10-6
11.191
3.40×10-14
2.719
5.10×10-4
∞
0.013
17.688
1.73×10-8
0.304
2.30×10-6
3.267
2.16×10-3
∞
2.07×10-5
0.046
3.51×10-14
56.713
1.89×10-14
∞
3.42×10-5
32.759
5.97×10-9
2.350
0.025

Parkinson’s disease
OR
FDR
2.439
0.010
2.320
0.014
2.563
0.024
2.416
0.006
4.163
0.030
2.126
0.033
2.519
0.005
2.139
0.030
3.011
0.048
2.631
0.026
2.116
0.030
2.308
0.034
2.437
0.010
2.437
0.013
2.443
0.044

OR: odds ratio, FDR: false discovery rate; ∞: infinite value resulting from have 0’s values
in off-diagonal corresponding 2×2 tables.

Analysis at the network level

gene interactions (as stated in the Methods section). The
corresponding networks for the information on coexpression of the 15 overlapped genes between
Parkinson’s disease and gastric cancer (through the
calculation of Spearman’s correlation coefficients), are
presented in Figure 3. Among the gastric cancer
patients, all the 15 overlapping genes appear to be

Using the String software, only four connections
(CSNK1D to ZBTB16, ZBTB16 to RNF19B, RNF19B
to CSNK1D, and ZBTB16 to CEBPA) were revealed for
the 15 overlapped genes. As a result, a data-driven
strategy was used to obtain the information on gene-to-

Figure 2. ROC curves showing predictive performance of the identified 15-gene signature. (A) For Parkinson’s disease. (B) For
gastric cancer. Here, external validation sets were used. AUC, area under curve; GC, gastric cancer; PD, Parkinson’s disease.
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isolated from each other, whereas among the controls,
three gene pairs (SPINT1 and GMDS, GMDS and
TNRC18, and CSNK1D and RNF19B) are connected.
This may correspond to a loss of connectivity in the
gastric cancer patients, which is consistent with the
findings by Anglani et al. [38]. In contrast, for
Parkinson’s disease patients, five pairs of connections
were gained, six pairs were lost, while five pairs
remained connected. Interestingly, two loss-ofconnectivity pairs for gastric cancer (SPINT1 and
GMDS, and GMDS and TNRC18) were observed
among the five gain-of-connectivity pairs for
Parkinson’s disease, implying a possible opposite
direction of change at the gene-to-gene interaction level
for Parkinson’s disease and gastric cancer.

turnover and in the proteolytic activation of hormones
and growth factors. CTSD may be involved in the
pathogenesis of several diseases, including breast
cancer and Alzheimer's disease. The pathways related to
CTSD include lysosome and degradation of the
extracellular matrix, and related GO annotations include
aspartic-type endopeptidase activity. Liu et al. [40]
showed through western blot assay that the CTSD
protein is significantly up-regulated in the gastric cancer
tissues compared to the normal tissues. Another study
[41] showed this regulation pattern using
immunohistochemistry. On the other hand, the CTSD
levels in Parkinson’s disease patients show a consistent
over-expression pattern across several studies, as
pointed out in a recent review [42].

DISCUSSION

The pathways, with which glutathione peroxidase 3
(GPX3) has been associated, include folate metabolism
and detoxification of reactive oxygen species, and GO
terms are transcription factor binding and selenium
binding. In a recent study [43], using two microarray
data, viz, GSE99039 (the dataset we used in this study)
and GSE72267 as the training set, GPX3 was identified
as a DEG for Parkinson’s disease as well. Subsequently,
the over-expression of this gene in the diseased tissues
was experimentally validated by qRT-PCR. In contrast,
GPX3 expression was shown to be lower in gastric
cancer patients compared to the normal tissues, and the
overexpression of GPX3 can inhibit gastric cancer cell
migration and invasion [43]. Meanwhile, another recent
study [44] used the The Cancer Genomic Atlas data to
show that GPX3 was hypermethylated in gastric cancer,
which may consequently increase the possibility of
tumor recurrence.

Biological relevance
The biological relevance of the 15 overlapping genes to
gastric cancer and Parkinson’s disease was explored in
the GeneCards database [39], and PubMed was searched
for more recent information. The GeneCards [39] search
revealed that nine of the 15 overlapping DEGs are
directly associated with gastric cancer. Meanwhile, four
genes related to Parkinson’s disease (CTSD, GPX3,
CSNK1D, and UBE2M) are included in the nine genes
directly related to gastric cancer. The remaining
overlapping genes are all indirectly associated with either
gastric cancer or Parkinson’s disease.
According to the GeneCards [39], Cathespin D (CTSD)
exhibits pepsin-like activity and plays a role in protein

Figure 3. Data-driven gene-to-gene interaction networks of the overlapped 15 genes. (A) For the control group in Parkinson’s
disease. (B) For the diseased group in Parkinson’s disease. (C) For the control group in gastric cancer. PD, Parkinson’s disease; GC, gastric
cancer. The edges highlighted in red are unique for the corresponding categories. Specifically, among the gastric cancer patients, all the 15
overlapped genes are isolated from each other, whereas among the controls, 3 gene pairs (SPINT1 and GMDS, GMDS and TNRC18, and
CSNK1D and RNF19B) are connected. In contrast, for Parkinson’s disease patients 5 pairs of connections are gained, 6 pairs are lost, while 5
pairs remain connected.
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The related pathways of casein kinase 1 delta
(CSNK1D) are neuroscience and organelle biogenesis
and maintenance. GO annotations related to this gene
include transferase activity, transferring phosphoruscontaining groups and protein tyrosine kinase activity.
UBE2M gene codes for Ubiquitin conjugating enzyme
E2 M protein. Among its related pathways are signaling
by GPCR and regulation of activated PAK-2p34 by
proteasome mediated degradation. GO annotations
related to this gene include ubiquitin-protein transferase
activity and ubiquitin protein ligase activity. As far as
these two genes are considered, there are no recent
experiments reported in PubMed to provide more
support on their relevance to either Parkinson’s disease
or gastric cancer.

(GPL570), and human gene 1.0 ST (GPL6244) because
a large number of chips are required to estimate the null
mean and variance in the method.
To acquire a sufficient statistical power to evaluate the
association between these two diseases, the sample sizes
of both gastric cancer and Parkinson’s disease cohorts
need to be large. As a result, two microarray experiments
in the NIH’s Gene Expression Omnibus (GEO) repository
from the National Institute of Health were selected:
GSE99039 [46] for Parkinson’s disease and GSE66229
[47] for gastric cancer. In addition, GSE20146 [22] and
GSE79973 [28] were used as external validation sets to
evaluate the predictive performance of the resulting gene
list. The demographical characteristics of these four
studies are summarized in Table 2.

Of note, a long non-coding RNA, steroid receptor RNA
activator 1 (SRA1), has been experimentally validated to
play roles in a variety of cancer types, including breast
cancer, prostate cancer, and liver cancer. While there is
no experimental evidence on its association with gastric
cancer and Parkinson’s disease, it was predicted to
associate with these two diseases using computational
methods in the lncRNADisease2.0 database [45].
Therefore, exploration of the potential association
between these two diseases in terms of lncRNAs may
be a promising research avenue.

Pre-processing procedures
Raw data (CEL files) of the two microarray experiments
were downloaded from the GEO repository and preprocessed using the fRMA algorithm [48], which can
provide effective control on batch effects and enable preprocessing of a single chip [48–50]. For those multiple
probe sets matched to the identical gene, the one with the
largest absolute log fold change was retained.
Statistical methods

CONCLUSIONS
Barcode algorithm
The barcode algorithm proposed by McCall et al. [33]
transformed the actual expression values into binary
barcode values, and the expressed genes are coded with
1’s and the silenced genes are coded with 0’s. Briefly,
for each gene, a mixture model in the algorithm is used
to fit the silenced and expressed distribution of observed
log2 transformed intensity values. The mixture model is
expressed as:

Using gene expression profiles and the barcode
algorithm, we show that two distinct diseases,
Parkinson’s disease, and gastric cancer are indeed
linked to each other at the molecular level. Our future
work will focus on two questions, whether the
association is positive or negative and whether and how
race or certain environmental factors influence the
association between these two diseases.

Yig | g ~ (1 − pg )  N ( g , g2 ) + pg  U ( g , S g )

To conclude, the present study may serve as a pilot
study, and it may inspire more research to evaluate the
relationship between cancer and neurodegenerative
diseases from the perspective of genes and their
interaction networks.

 g ~ N ( ,  2 )

 g2 ~ IG ( ,  )

MATERIALS AND METHODS

where Yig is the log2 expression value for gene g in
sample i, and follows a normal distribution of N (μg, τg2)
when gene g is silenced or has a uniform distribution of
U(μg, Sg) when it is expressed. Here, μg denotes the
mean of silenced genes, and Sg denotes the saturation
value (i.e., the upper limit of gene expression values).
Then, μg and τg2 for gene g are assumed to follow
normal and inverse gamma distributions, respectively.
With a hierarchical model structure, and in particular
the introduction of higher-level parameters (α, β, ξ, and
λ), more stable estimates of variances for silenced genes

Experimental data
The barcode algorithm was used in this study to identify
differentially expression genes between the diseased
group and the control group. Therefore, some
restrictions on the microarray platforms were imposed.
Specifically, for human studies, chips that are
applicable to the barcode algorithm include Affymetrix
U133A (GPL96), U133 2.0 (GPL571), U133plus 2.0

www.aging-us.com
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Table 2. Characteristics of microarray experiments in this study.
Training set
GSE99039 (Parkinson’s
disease)
GSE66229 (gastric
cancer)
Validation set
GSE20146 (Parkinson’s
disease)
GSE79973 (gastric
cancer)

Reference

Raw data

Platform

Diseased

Controls

Race

[46]

Yes

GPL570

205

233

Western

[47]

Yes

GPL570

303

101

Asian

[22]

Yes

GPL570

10

10

Western

[28]

Yes

GPL570

10

10

Asian

are expected because the information across genes is
borrowed and shared across genes, leading to a
shrinkage of estimates for individual genes toward the
overall level.

implemented by the barcode function in the R fRMA
package, and the default value of C was used.

To determine if a gene is silenced or expressed, the
standardized intensity value, (yig − μg)/τg, was calculated.
Upon a pre-determined cutoff value C, the expression
barcode for a gene, a vector of 1’s and 0’s is defined as,

On the barcode values, the genes with all values of either
1’s or 0’s for the respective gastric cancer and Parkinson’s
disease cohorts were eliminated, and finally, 8,392 probesets were fed into the downstream analysis.

(

Differentially expressed genes

)


 1  − ( yig −  g ) /  g  C
barcodeig = 

 0 otherwise

To determine if the expressed ratios differed in the
diseased group versus the control group, Fisher’s exact
test for individual genes was carried out upon the
barcode values. Genes with a false discovery rate (FDR)
of < 0.05, which was calculated through the BenjaminiHochberg (BH) procedure [51] to adjust for multiple
testing issue, were considered as differentially
expressed genes in the respective gastric cancer and
Parkinson’s disease cohorts. The flowchart of the
proposed procedure is given in Figure 4.

where Φ is the cumulative density function of a
standard normal, parameter estimation in this
hierarchical model is done using a modified
expectation-maximization algorithm (the details of the
barcode are available in the supplementary material of a
previous study [33]). The barcode algorithm was

Figure 4. Flowchart illustrating how the differentially expressed genes are identified with the aid of barcode algorithm.
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